Oklahoma 2025 Regular Session

Oklahoma Senate Bill SB574 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
3		-	ENGR. S. B. NO. 574 Page 1 1
	3	+	SENATE FLOOR VERSION - SB574 SFLR Page 1
	4	+	(Bold face denotes Committee Amendments) 1
4	5		2
5	6		3
6	7		4
7	8		5
8	9		6
9	10		7
10	11		8
11	12		9
12	13		10
13	14		11
14	15		12
15	16		13
16	17		14
17	18		15
18	19		16
19	20		17
20	21		18
21	22		19
22	23		20
23	24		21
24	25		22
25	26		23
26	27		24
27	28
28		-	ENGROSSED SENATE
29		-	BILL NO. 574 By: Haste of the Senate
	29	+	SENATE FLOOR VERSION
	30	+	February 26, 2025
	31	+	AS AMENDED
	32	+
	33	+	SENATE BILL NO. 574 By: Haste of the Senate
30	34
31	35		and
32	36
33	37		Roe of the House
34	38
35	39
36	40
37	41
38		-	An Act relating to the Attorney General; amending 74
39		-	O.S. 2021, Section 30.5, as last amended by Section
40		-	3, Chapter 124, O.S.L. 2024 (74 O.S. Supp. 2024,
41		-	Section 30.5), which relates to definitions used in
42		-	the Political Subdivisions Opioid Abatement Grants
43		-	Act; modifying definitions; removing obsolete
44		-	language; amending 74 O.S. 2021, Section 30.6, which
45		-	relates to the Oklahoma Opioid Abatement Revolving
46		-	Fund; authorizing the Office of the Attorney General
47		-	to use certain funds for specified purpose; requiring
48		-	certain approval of projects; updating statutory
49		-	reference; amending 74 O.S. 2021, Section 30.8, as
50		-	amended by Section 2, Chapter 75, O.S.L. 2022 (74
51		-	O.S. Supp. 2024, Section 30.8), which relates to
52		-	disbursement of grants; broadening applicability of
53		-	certain provisions; updating statutory language; and
54		-	providing an effective date.
	42	+
	43	+	[ Attorney General - definitions - Revolving Fund -
	44	+	approval of projects - accrual of income and
	45	+	investment return - grants - provisions - effective
	46	+	date ]
	47	+
55	48
56	49
57	50
58	51		BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
59	52		SECTION 1. AMENDATORY 74 O.S. 2021, Section 30.5, as
60	53		last amended by Section 3, Chapter 124, O.S.L. 2024 (74 O.S. Supp.
61	54		2024, Section 30.5), is amended to read as follows:
62	55		Section 30.5. As used in the Political Subdivisions Opioid
63	56		Abatement Grants Act:
64	57		1. “Approved purpose” and “approved purposes” mean evidence-
65	58		based, forward-looking strategies, programming and services used to:
	59	+	a. expand the availability of treatment for individuals
	60	+	affected by opioid use disorders, co -occurring
	61	+	substance use disorders and mental health issues,
	62	+	b. develop, promote and provide evidence -based opioid use
	63	+	prevention strategies,
66	64
67		-	ENGR. S. B. NO. 574 Page 2 1
	65	+	SENATE FLOOR VERSION - SB574 SFLR Page 2
	66	+	(Bold face denotes Committee Amendments) 1
68	67		2
69	68		3
70	69		4
71	70		5
72	71		6
73	72		7
74	73		8
75	74		9
76	75		10
77	76		11
78	77		12
79	78		13
80	79		14
81	80		15
82	81		16
83	82		17
84	83		18
85	84		19
86	85		20
87	86		21
88	87		22
89	88		23
90	89		24
91	90
92		-	a. expand the availability of treatment for individuals
93		-	affected by opioid use disorders, co -occurring
94		-	substance use disorders and menta l health issues,
95		-	b. develop, promote and provide evidence -based opioid use
96		-	prevention strategies,
97	91		c. provide opioid use disorder and co -occurring substance
98	92		use disorder avoidance and awareness education,
99	93		d. decrease the oversupply of licit and illicit opioids,
100	94		e. support recovery from addiction services performed by
101	95		qualified and appropriately licensed providers,
102	96		f. treat opioid use, abuse and disorders including ea rly
103	97		intervention screening, counseling and support,
104	98		g. support individuals in treatment and recovery from
105	99		opioid use, abuse and disorder,
106	100		h. provide programs or services to connect individuals
107	101		with opioid use, abuse or disorder, or who are at risk
108	102		of developing opioid use disorder, co -occurring
109	103		substance use disorder and mental health issues, with
110	104		treatment and counseling programs and services,
111	105		i. address the needs of individuals who are involved, or
112	106		who are at risk of becoming in volved, in the criminal
113	107		justice system due to opioid use, abuse or disorder
114	108		through programs or services in municipal and county
115	109		criminal judicial systems including prearrest and
	110	+	postarrest diversion programs, pretrial services and
	111	+	drug or recovery courts,
	112	+	j. address the needs of pregnant or parenting women with
	113	+	opioid use, abuse or disorder and their families,
116	114
117		-	ENGR. S. B. NO. 574 Page 3 1
	115	+	SENATE FLOOR VERSION - SB574 SFLR Page 3
	116	+	(Bold face denotes Committee Amendments) 1
118	117		2
119	118		3
120	119		4
121	120		5
122	121		6
123	122		7
124	123		8
125	124		9
126	125		10
127	126		11
128	127		12
129	128		13
130	129		14
131	130		15
132	131		16
133	132		17
134	133		18
135	134		19
136	135		20
137	136		21
138	137		22
139	138		23
140	139		24
141	140
142		-	postarrest diversion programs, pretrial services and
143		-	drug or recovery courts,
144		-	j. address the needs of pregnant or parenting women with
145		-	opioid use, abuse or disorder and their families,
146	141		k. address the needs of parents and caregivers caring for
147	142		babies with neonatal abstinence syndrome,
148	143		l. support efforts to prevent overprescribing an d ensure
149	144		appropriate prescribing and dispensing of opioids,
150	145		m. support efforts to discourage or prevent misuse of
151	146		opioids including the oversupply of licit and illicit
152	147		opioids,
153	148		n. support efforts to prevent or reduce overdose deaths
154	149		or other opioid-related harms including through
155	150		increased availability and distribution of naloxone
156	151		and other drugs that treat overdoses for use by first
157	152		responders, persons who have experienced an overdose
158	153		event, families, schools, community -based service
159	154		providers, social work ers and other members of th e
160	155		public,
161	156		o. reimburse or fund law enforcement and emergency
162	157		responder expenditures relating to the opioid epidemic
163	158		including costs of responding to emergency medical or
164	159		police calls for service, equipment, treatment or
165	160		response alternatives, mental health response training
	161	+	and training for law enforcement and emergency
	162	+	responders as to appropriate practices and precautions
	163	+	when dealing with opioids or individuals who are at
	164	+	risk of opioid overdose or death,
166	165
167		-	ENGR. S. B. NO. 574 Page 4 1
	166	+	SENATE FLOOR VERSION - SB574 SFLR Page 4
	167	+	(Bold face denotes Committee Amendments) 1
168	168		2
169	169		3
170	170		4
171	171		5
172	172		6
173	173		7
174	174		8
175	175		9
176	176		10
177	177		11
178	178		12
179	179		13
180	180		14
181	181		15
182	182		16
183	183		17
184	184		18
185	185		19
186	186		20
187	187		21
188	188		22
189	189		23
190	190		24
191	191
192		-	and training for law enforcement and emergency
193		-	responders as to appropriat e practices and precautions
194		-	when dealing with opioids or individuals who are at
195		-	risk of opioid overdose or death,
196	192		p. reimburse attorney fees and allowable expenses
197	193		directly related to opioid litigation incurred as part
198	194		of legal services agreements entered into before May
199	195		21, 2020,
200	196		q. support efforts to provide leadership, planning and
201	197		coordination to abate the opioid epidemic through
202	198		activities, programs or strategies for prevention and
203	199		recovery models including regional intergovernmental
204	200		efforts and not-for-profit agency support,
205	201		r. support education of youths regarding the dangers of
206	202		opioid use, abuse and addiction,
207	203		s. fund training relative to any approved purpose ,
208	204		t. monitor, surveil and evaluate opioid use, abuse or
209	205		disorder,
210	206		u. provide educational and health care services related
211	207		to nonopioid treatment alternatives, or
212	208		v. provide opioid abatement as identified by the Oklahoma
213	209		Opioid Abatement Board as consistent with the purpose
214	210		of the Political Subdivisions Opioid Abatement Grants
215	211		Act.
	212	+	Provided that, such strategies, programming and services occurred on
	213	+	or after January 1, 2015 .
216	214
217		-	ENGR. S. B. NO. 574 Page 5 1
	215	+	SENATE FLOOR VERSION - SB574 SFLR Page 5
	216	+	(Bold face denotes Committee Amendments) 1
218	217		2
219	218		3
220	219		4
221	220		5
222	221		6
223	222		7
224	223		8
225	224		9
226	225		10
227	226		11
228	227		12
229	228		13
230	229		14
231	230		15
232	231		16
233	232		17
234	233		18
235	234		19
236	235		20
237	236		21
238	237		22
239	238		23
240	239		24
241	240
242		-	Provided that, such strategies, programming and services occurred on
243		-	or after January 1, 2015 .
244	241		Approved purpose also includes any approved uses as autho rized
245	242		by opioid-related settlement agreements in which the State of
246	243		Oklahoma is a litigant or participant ;
247	244		2. “Board” means the Oklahoma Opioid Abatement Board;
248	245		3. “Eligible participant ” means any political subdivision
249	246		impacted by the opioid crisis;
250	247		4. “Nonapproved purpose” and “nonapproved purposes ” mean
251	248		strategies, programming and services not falling within the
252	249		definition of approved purpose or approved purposes as defined in
253	250		this section;
254	251		5. “Opioid funds” means all monetary amounts obtained through a
255	252		settlement or judgment b y the Attorney General on behalf of this
256	253		state related to opioid litigation involving pharmaceutical supply
257	254		chain participants including the Purdue Political Subdivisions
258	255		Subdivision Fund but excluding all other funds received pu rsuant to
259	256		the Purdue Settlement Agreement;
260	257		6. “Opioid grant awards” means grants funded from the Oklahoma
261	258		Opioid Abatement Revolving Fund, awarded pursuant to the provisions
262	259		of the Political Subdivisions Opioid Abatement Grants Act;
263	260		7. “Pharmaceutical supply chain” means the process and channels
264	261		through which controlled substances are manufactured, marketed,
265	262		promoted, distributed or dispensed;
266	263
267		-	ENGR. S. B. NO. 574 Page 6 1
	264	+	SENATE FLOOR VERSION - SB574 SFLR Page 6
	265	+	(Bold face denotes Committee Amendments) 1
268	266		2
269	267		3
270	268		4
271	269		5
272	270		6
273	271		7
274	272		8
275	273		9
276	274		10
277	275		11
278	276		12
279	277		13
280	278		14
281	279		15
282	280		16
283	281		17
284	282		18
285	283		19
286	284		20
287	285		21
288	286		22
289	287		23
290	288		24
291	289
292	290		8. “Pharmaceutical supply chain participant ” means any entity
293	291		that engages in or has engaged in the manufacture, marketing,
294	292		promotion, distribution or dispensing of an opioid analgesic;
295	293		9. “Political subdivision ” and “political subdivisions ” have
296	294		the same meaning as provided in subparagraphs a, b, c and d of
297	295		paragraph 11 of Section 152 of Title 51 of the Oklahoma S tatutes.
298	296		Political subdivision also means the board of regents or board of
299	297		trustees of a state educational institution which is a member of The
300	298		Oklahoma State System of Higher Education ;
301	299		10. “Purdue Political Subdivision Fund ” means the Twelve
302	300		Million Five Hundred Thousand Dollars ($12,500,000.00) plus any
303	301		interest accrued thereon received from the Revive Oklahoma Health
304	302		Foundation consisting of funds received from the Purdue Settlement
305	303		Agreement designed for distribution to political subdivisions which
306	304		have executed a release of l egal claims as required by the Purdue
307	305		Settlement Agreement; and
308	306		11. “Purdue Settlement Agreement ” means the settlement
309	307		agreement entered into by this state and Purdue Pharma L.P., Purdue
310	308		Pharma, Inc. and the Purdue Frederick Com pany on March 26, 2019, and
311	309		approved by the Court on April 2, 2019.
312	310		SECTION 2. AMENDATORY 74 O.S. 2021, Section 30.6, is
313	311		amended to read as follows:
314	312		Section 30.6. A. There is hereby created in the State Treasury
315	313		a revolving fund for the Office of the Atto rney General to be
316	314
317		-	ENGR. S. B. NO. 574 Page 7 1
	315	+	SENATE FLOOR VERSION - SB574 SFLR Page 7
	316	+	(Bold face denotes Committee Amendments) 1
318	317		2
319	318		3
320	319		4
321	320		5
322	321		6
323	322		7
324	323		8
325	324		9
326	325		10
327	326		11
328	327		12
329	328		13
330	329		14
331	330		15
332	331		16
333	332		17
334	333		18
335	334		19
336	335		20
337	336		21
338	337		22
339	338		23
340	339		24
341	340
342	341		designated the “Oklahoma Opioid Abatement Revolving Fund ”. The fund
343	342		shall be a continuing fund, not subject to fiscal year limitations,
344	343		and shall consist of all opioid funds obtained through a settlement
345	344		or judgment by the Attorney General on behalf of the State of
346	345		Oklahoma related to opioid litigation involving pharmaceutical
347	346		supply chain participants:
348	347		1. Designated for deposit in the fund; or
349	348		2. Appropriated to the fund by the Legislature.
350	349		B. Provided that the Purdue Political Subdivisions Subdivision
351	350		Fund shall be maintained in a segregated State Treasury fund within
352	351		the Oklahoma Opioid Abatement Revolving Fund, and that the Purdue
353	352		Political Subdivisions Subdivision Fund shall not be commingled with
354	353		other opioid funds deposited in or appropriated to the Oklahoma
355	354		Opioid Abatement Revolving Fund.
356	355		C. The Office of the Attorney General may use not more than ten
357	356		percent (10%) of the funds appropriated to the Oklahoma Opioid
358	357		Abatement Revolving Fund for statewid e opioid abatement projects
359	358		that constitute an approved use under the Political Subdivisions
360	359		Opioid Abatement Grants Act. The Oklahoma Opioid Abatement Board
361	360		shall approve all statewide opioid abatement projects described in
362	361		this subsection.
363		-	D. ~~All monies accruing to the credit~~ of ~~the fund are hereby~~
364		-	~~appropriated and may be budgeted and expended by~~ the ~~Attorney~~
	362	+	D. Notwithstanding any other provisions of law, income and
	363	+	investment return on fund principal shall accrue to the fund.
365	364
366		-	ENGR. S. B. NO. 574 Page 8 1
	365	+	SENATE FLOOR VERSION - SB574 SFLR Page 8
	366	+	(Bold face denotes Committee Amendments) 1
367	367		2
368	368		3
369	369		4
370	370		5
371	371		6
372	372		7
373	373		8
374	374		9
375	375		10
376	376		11
377	377		12
378	378		13
379	379		14
380	380		15
381	381		16
382	382		17
383	383		18
384	384		19
385	385		20
386	386		21
387	387		22
388	388		23
389	389		24
390	390
	391	+	E. All monies accruing to the credit of the fund are hereby
	392	+	appropriated and may be budgeted and expended by the Attorney
391	393		General for the purpose of funding opioid grant awa rds as authorized
392	394		by this act the Political Subdivisions Opioid Abatement Grants Act .
393	395		SECTION 3. AMENDATORY 74 O.S. 2021, Section 30.8, as
394	396		amended by Section 2, Chapter 75, O.S.L. 2022 (74 O.S. Supp. 202 4,
395	397		Section 30.8), is amended to read as follows:
396	398		Section 30.8. A. 1. The Oklahoma Opioid Abatement Board shall
397	399		conduct an initial disbursement one or more disbursements of opioid
398	400		grant awards to participating eligible participants. Such opioid
399	401		grant awards shall be allocated amo ngst the different participating
400	402		eligible participants based on the following criteria:
401	403		a. the number of people per capita suffering from opioid
402	404		use disorder in the participating political
403	405		subdivision, or in the absence of such i nformation,
404	406		the opioid prescription rate in the political
405	407		subdivision compared to the national average opioid
406	408		prescription rate,
407	409		b. the number of opioid overdose deaths in the
408	410		participating political subdivision,
409	411		c. the amount of opioids distributed within the
410	412		participating politica l subdivision, and
411	413		d. the amount of attorney fees and allowable expenses
412	414		associated with legal services agreements directly
413		-	related to opioid litigation incurred as part of legal
414	415
415		-	ENGR. S. B. NO. 574 Page 9 1
	416	+	SENATE FLOOR VERSION - SB574 SFLR Page 9
	417	+	(Bold face denotes Committee Amendments) 1
416	418		2
417	419		3
418	420		4
419	421		5
420	422		6
421	423		7
422	424		8
423	425		9
424	426		10
425	427		11
426	428		12
427	429		13
428	430		14
429	431		15
430	432		16
431	433		17
432	434		18
433	435		19
434	436		20
435	437		21
436	438		22
437	439		23
438	440		24
439	441
	442	+	related to opioid litigation incurred as part of legal
440	443		services agreements entered into before May 21, 20 20,
441	444		or
442	445		e. any other criteria established by the Board .
443	446		2. Grant awards shall be subject to legal services agreements
444	447		entered into by eligible participants.
445	448		3. Initial opioid Opioid grant awards as provided for in this
446	449		subsection shall be listed in an opi oid grant award distributio n
447	450		table reviewed and approved by the Board to ensure that such awards
448	451		adhere to the criteria adopted by the Board.
449	452		B. Following the awarding of opioid grant awards pursuant to
450	453		subsection A of this section, any remaining unencumb ered balance in
451	454		Funds accrued in the Oklahoma Opioid Abatement Revolving Fund shall
452	455		be available to the Board to award as grants to eligible
453	456		participants; provided such awards shall only be utilized by
454	457		eligible participants for approved purposes.
455	458		C. In the event an eligible partici pant merges, dissolves or
456	459		ceases to exist, any remaining allocations of an awarded opioid
457	460		grant award in excess of Five Hundred Dollars ($500.00) shall be
458	461		reallocated equitably based on the composition of the successor
459	462		eligible participant or the successor eligible participants.
460	463		SECTION 4. This act shall become effective November 1, 2025.
461		-
462		-	ENGR. S. B. NO. 574 Page 10 1
463		-	2
464		-	3
465		-	4
466		-	5
467		-	6
468		-	7
469		-	8
470		-	9
471		-	10
472		-	11
473		-	12
474		-	13
475		-	14
476		-	15
477		-	16
478		-	17
479		-	18
480		-	19
481		-	20
482		-	21
483		-	22
484		-	23
485		-	24
486		-
487		-	Passed the Senate the 24th day of March, 2025.
488		-
489		-
490		-
491		-	Presiding Officer of the Senate
492		-
493		-
494		-	Passed the House of Represe ntatives the ____ day of __________,
495		-	2025.
496		-
497		-
498		-
499		-	Presiding Officer of the House
500		-	of Representatives
501		-
	464	+	COMMITTEE REPORT BY: COMMITTEE ON APPROPRIATIONS
	465	+	February 26, 2025 - DO PASS AS AMENDED